Form 4: Q32 Bio CSO Sells Shares for Tax Obligations

Q32 Bio's Chief Scientific Officer, Shelia M. Violette, sold 2,815 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Shelia M. Violette, Chief Scientific Officer of Q32 Bio Inc. (QTTB), reported a sale of common stock.
• The transaction involved the disposition of 2,815 shares of common stock on February 25, 2026.
• The shares were sold at a weighted average price of $4.5144 per share, with individual sales ranging from $4.35 to $4.69.
• The sale was non-discretionary, executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Shelia M. Violette directly beneficially owns 55,569 shares of common stock.
• Additionally, 36,277 shares are indirectly beneficially owned through Violette Holdings LLC, where the reporting person is a manager and disclaims beneficial ownership except for pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is non-discretionary and for tax purposes, not indicative of a change in management's sentiment towards the company's prospects. The underlying RSU vesting is a positive for executive compensation.

Positives

• The underlying event of restricted stock unit vesting indicates compensation realization for the Chief Scientific Officer, which can be a positive for executive retention and motivation.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sale represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• These sales were automatic and not in the discretion of the Reporting Person.

Industry Context

StockSavvy.ai notes that sales of company stock by executives to cover tax withholding obligations upon the vesting of restricted stock units are a common and routine occurrence across industries, reflecting standard compensation practices and tax requirements.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary tax-related sale by an insider, not signaling a change in company fundamentals or insider confidence.
• Employees: No direct impact mentioned.

Key Dates

Keywords

Q32 Bio, QTTB, Insider Transaction, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Shelia M. Violette, Chief Scientific Officer